(1.23%) 5 126.68 points
(1.16%) 38 670 points
(1.95%) 16 151 points
(-1.06%) $78.11
(5.60%) $2.15
(-0.03%) $2 309.00
(-0.36%) $26.73
(0.21%) $964.65
(-0.34%) $0.929
(-1.14%) $10.87
(-0.12%) $0.797
(0.38%) $91.47
4 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 8.20%
0.04% $ 47.51
@ $47.59
Wydano: 3 geg. 2024 @ 19:57
Zwrot: -0.17%
Poprzedni sygnał: geg. 2 - 22:54
Poprzedni sygnał:
Zwrot: 0.06 %
Live Chart Being Loaded With Signals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 941 817 |
Średni wolumen | 1.42M |
Kapitalizacja rynkowa | 5.73B |
EPS | $0 ( 2024-05-02 ) |
Następna data zysków | ( $-0.550 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -10.68 |
ATR14 | $1.540 (3.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Sullivan Timothy Eugene | Sell | 14 164 | Common Stock |
2024-04-18 | Sullivan Timothy Eugene | Buy | 14 164 | Common Stock |
2024-04-12 | Dunlop A. Sinclair | Buy | 1 500 | Common Stock |
2024-04-12 | Dunlop A. Sinclair | Sell | 1 500 | Stock Option (Right to Buy) |
2024-04-08 | Deschatelets Pascal | Buy | 69 107 | Common Stock |
INSIDER POWER |
---|
2.39 |
Last 100 transactions |
Buy: 1 047 810 | Sell: 959 444 |
Wolumen Korelacja
Apellis Pharmaceuticals Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
BRIVU | 0.949 |
MSDAU | 0.948 |
TIOAU | 0.945 |
VLAT | 0.945 |
INZY | 0.945 |
NVCN | 0.945 |
LDHA | 0.943 |
ALXN | 0.941 |
GVCI | 0.941 |
TIOA | 0.94 |
10 Najbardziej negatywne korelacje | |
---|---|
NDRA | -0.967 |
MNPR | -0.95 |
DFFN | -0.948 |
ENLV | -0.947 |
LSAQ | -0.945 |
MMAT | -0.945 |
JG | -0.942 |
ATNF | -0.942 |
MAGS | -0.941 |
ASRV | -0.938 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Apellis Pharmaceuticals Korelacja - Waluta/Towar
Apellis Pharmaceuticals Finanse
Annual | 2023 |
Przychody: | $396.59M |
Zysk brutto: | $336.38M (84.82 %) |
EPS: | $-4.45 |
FY | 2023 |
Przychody: | $396.59M |
Zysk brutto: | $336.38M (84.82 %) |
EPS: | $-4.45 |
FY | 2022 |
Przychody: | $75.42M |
Zysk brutto: | $69.79M (92.53 %) |
EPS: | $-6.15 |
FY | 2021 |
Przychody: | $66.56M |
Zysk brutto: | $61.36M (92.19 %) |
EPS: | $-8.84 |
Financial Reports:
No articles found.
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej